A. Ohtsu

发表

Association of p53 protein expression with responses and survival of patients with locally advanced esophageal carcinoma treated with chemoradiotherapy.

S. Yoshida, K. Muro, A. Ohtsu, 1996, Japanese journal of clinical oncology.

Exposure–response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer

Tae You Kim, D. Ferry, A. Ohtsu, 2018, Gastric Cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Yoon-Koo Kang, Taroh Satoh, Lin Shen, 2010, The Lancet.

Additional surgery for non-curative resection after endoscopic submucosal dissection for gastric cancer: a retrospective analysis of 200 cases

K. Kaneko, A. Ochiai, T. Nishida, 2017, Surgery Today.

Squamous cell carcinoma in situ at oropharyngeal and hypopharyngeal mucosal sites

Yasushi Sano, Y. Sano, S. Yoshida, 2004, Cancer.

A Micro-Vascular Architecture with NBI Colonoscopy Is Useful to Predict Invasiveness and Allow Patients to Select for Endoscopic Resection Or Surgical Resection

Hiroaki Ikematsu, Yasushi Sano, Y. Sano, 2007 .

Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2010, Cancer Chemotherapy and Pharmacology.

Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer.

K. Muro, A. Ohtsu, M. Watanabe, 2021, Japanese journal of clinical oncology.

Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with genfinitib (ZD1839)

J. Baselga, F. Rojo, J. Albanell, 2003 .

Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912.

A. Ohtsu, H. Nishisaki, Y. Hamamoto, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604)

A. Sato, K. Nihei, K. Muro, 2015, Cancer science.

Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors

J. Watanabe, M. Robson, A. Ohtsu, 2014, Cancer Chemotherapy and Pharmacology.

Acetaldehyde production by non‐pathogenic Neisseria in human oral microflora: Implications for carcinogenesis in upper aerodigestive tract

H. Sasaki, H. Esumi, Y. Kashiwase, 2000, International journal of cancer.

Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant

Teruhiko Yoshida, N. Saijo, K. Muro, 2012, Immunogenetics.

Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with bone metastasis

H. Tajiri, Y. Sano, S. Yoshida, 2000, Gastric Cancer.

Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.

K. Kaneko, T. Yano, H. Ikematsu, 2010, Japanese journal of clinical oncology.

Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors

A. Ohtsu, H. Murakami, T. Yoshino, 2011, Cancer Chemotherapy and Pharmacology.

Current status and future prospects of chemotherapy for metastatic gastric cancer: a review

A. Ohtsu, 2005, Gastric Cancer.

Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer.

S. Yoshida, A. Ohtsu, M. Muto, 2002, Gastrointestinal endoscopy.

Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15.

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2007, Drug metabolism and pharmacokinetics.

Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method

Teruhiko Yoshida, H. Sakamoto, A. Ohtsu, 2015, BMC Cancer.

' s response to reviews Title : Construction of possible integrated predictive index based on EGFR and ANXA 3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method

T. Hanai, H. Kurata, Teruhiko Yoshida, 2015 .

Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer.

N. Saijo, A. Ohtsu, Y. Sasaki, 1994, Journal of the National Cancer Institute.

FUNCTIONAL ANALYSIS OF SIX HUMAN ARYL HYDROCARBON RECEPTOR VARIANTS IN A JAPANESE POPULATION

Teruhiko Yoshida, N. Saijo, N. Kamatani, 2005, Drug Metabolism and Disposition.

Chemoradiotherapy for esophageal cancer: current status and perspectives

A. Ohtsu, 2004, International Journal of Clinical Oncology.

The latest advances in chemotherapy for gastrointestinal cancers

A. Ohtsu, 2003, International Journal of Clinical Oncology.

Chemotherapy and chemoradiotherapy for esophageal cancer.

A. Ohtsu, S. Yoshida, 1998, Critical reviews in oncology/hematology.

Feasibility and robustness of amplification refractory mutation system (ARMS)-based KRAS testing using clinically available formalin-fixed, paraffin-embedded samples of colorectal cancers.

H. Esumi, K. Tsuchihara, A. Ohtsu, 2011, Japanese journal of clinical oncology.

Esophageal stenosis after endoscopic mucosal resection of superficial esophageal lesions.

S. Yoshida, A. Ohtsu, M. Muto, 2003, Gastrointestinal endoscopy.

BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer

S. Nomura, A. Sato, A. Ohtsu, 2020, ESMO Open.

Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial

A. Ohtsu, T. Otsuki, T. Hamaguchi, 2013, International Journal of Clinical Oncology.

Clinical Cancer esearch cer Therapy : Clinical se I Study of NK 012 , a Novel SN-38 – Incorporating Micellar R oparticle , in Adult Patients with Solid Tumors

A. Ohtsu, Ken Kato, Y. Matsumura, 2010 .

Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus.

Narikazu Boku, Satoshi Ishikura, S. Yoshida, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison between neoadjuvant chemotherapy followed by surgery and definitive chemoradiotherapy for overall survival in patients with clinical Stage II/III esophageal squamous cell carcinoma (JCOG1406-A)

K. Muro, A. Ohtsu, H. Daiko, 2017, Japanese journal of clinical oncology.

Long-term results of salvage photodynamic therapy for patients with local failure after chemoradiotherapy for esophageal squamous cell carcinoma

K. Kaneko, T. Yano, K. Nihei, 2011, Endoscopy.

Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus.

T. Yano, K. Nihei, A. Ohtsu, 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Nonsurgical treatments for submucosal esophageal squamous cell carcinomas

A. Ohtsu, M. Muto, K. Minashi, 2007, Esophagus.

Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer.

S. Yoshida, A. Ohtsu, M. Tahara, 2005, Japanese journal of clinical oncology.

A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with T4 esophageal cancer: Japan Clinical Oncology Group trial (JCOG 9908)

S. Yoshida, K. Nihei, K. Muro, 2005, Esophagus.

Photodynamic therapy as salvage treatment for local failures after definitive chemoradiotherapy for esophageal cancer.

S. Yoshida, T. Yano, A. Ohtsu, 2005, Gastrointestinal endoscopy.

Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus.

A. Ohtsu, N. Boku, T. Fujii, 1995, Japanese journal of clinical oncology.

Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study.

S. Yoshida, I. Hyodo, A. Ohtsu, 2004, Japanese journal of clinical oncology.

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.

A. Ohtsu, W. Koizumi, A. Sawaki, 2009, The Lancet. Oncology.

Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407)

A. Ohtsu, Y. Hamamoto, Y. Shimada, 2016, Gastric Cancer.

Current Status of Chemotherapy for Advanced Gastric Cancer and Expectations for Molecular Targeting Therapy

A. Ohtsu, T. Doi, K. Shitara, 2012 .

Diagnostic findings in endoscopic screening of superficial colorectal neoplasia: results from a prospective study.

H. Tajiri, S. Yoshida, K. Muro, 1998, Japanese journal of clinical oncology.

Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.

T. Yano, K. Muro, A. Ohtsu, 2006, Japanese journal of clinical oncology.

Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial

E. Oki, Masato Nakamura, J. Sakamoto, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer

E. Oki, T. Yamanaka, Y. Maehara, 2019, JAMA oncology.

JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer

Y. Maehara, J. Sakamoto, K. Goto, 2019, Cancer Chemotherapy and Pharmacology.

Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer

T. Yamanaka, Y. Maehara, M. Mori, 2018, ESMO Open.

Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.

R. Goldberg, Po-Huang Lee, A. Ohtsu, 2012, Clinical colorectal cancer.

Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies

R. Goldberg, Po-Huang Lee, A. Ohtsu, 2012, Cancer medicine.

Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.

S. Yoshida, M. Asaka, A. Ohtsu, 2007, Japanese journal of clinical oncology.

Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

Marc Peeters, Yasuhiro Shimada, Ben Tran, 2015, The New England journal of medicine.

Integrated safety summary for trifluridine/tipiracil (TAS-102)

E. Van Cutsem, S. Kopetz, J. Bendell, 2018, Anti-cancer drugs.

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer

E. Van Cutsem, H. Lenz, F. Ciardiello, 2017, European journal of cancer.

TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study.

S. Nomura, A. Sato, A. Ohtsu, 2017, The Lancet. Oncology.

QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer

E. Van Cutsem, J. Tabernero, R. Mayer, 2017, ESMO Open.

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study

A. Grothey, A. Ohtsu, H. Hochster, 2016, BMC Cancer.

A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201).

S. Nomura, A. Sato, K. Muro, 2016, European journal of cancer.

Advances in Systemic Therapy for Metastatic or Advanced Gastric Cancer.

A. Ohtsu, K. Shitara, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer

A. Ohtsu, W. Koizumi, T. Yoshino, 2015, Investigational New Drugs.

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours

A. Ohtsu, W. Koizumi, T. Yoshino, 2012, British Journal of Cancer.

Phase I/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI.

Y. Inaba, Yozo Sato, Y. Arai, 2012, Journal of vascular and interventional radiology : JVIR.

Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer

S. Yoshida, T. Yano, M. Asaka, 2008, International Journal of Clinical Oncology.

Phase II study of oral S‐1 for treatment of metastatic colorectal carcinoma

K. Hirata, A. Ohtsu, K. Hirakawa, 2004, Cancer.

Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors

A. Ohtsu, Bing‐Bing Yang, T. Tamura, 2009, International Journal of Clinical Oncology.

TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial.

N. Sugimoto, K. Muro, A. Ohtsu, 2012, The Lancet. Oncology.

Effect of food on the pharmacokinetics of TAS‐102 and its efficacy and safety in patients with advanced solid tumors

H. Mukai, K. Goto, A. Ohtsu, 2016, Cancer science.

Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms

H. Matsumoto, A. Ohtsu, Y. Hamamoto, 2014, Journal of clinical pharmacology.

Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer

S. Nomura, A. Sato, A. Ohtsu, 2019, ESMO Open.

A case of inoperable esophageal carcinoma with hepatic and nodal metastases which showed a long-term survival after chemoradiotherapy including nedaplatin.

S. Yoshida, A. Ohtsu, N. Boku, 2000, Japanese journal of clinical oncology.

Biased discordance of KRAS mutation detection in archived colorectal cancer specimens between the ARMS-Scorpion method and direct sequencing.

M. Kojima, H. Esumi, A. Ochiai, 2011, Japanese journal of clinical oncology.

Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines.

I. Hyodo, A. Ohtsu, Y. Tanigawara, 2007, Japanese journal of clinical oncology.

Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies

A. Ohtsu, T. Doi, N. Boku, 2020, Investigational New Drugs.

Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer

I. Hyodo, A. Ohtsu, H. Onuma, 2013, Investigational New Drugs.

Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors.

Y. Sano, K. Muro, A. Ohtsu, 2006, Japanese journal of clinical oncology.

Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein–Barr virus status, and cancer genome alterations in metastatic gastric cancer

A. Ochiai, A. Ohtsu, T. Yoshino, 2018, Gastric Cancer.

O-0022RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF TAS-102 VS. PLACEBO, WITH BEST SUPPORTIVE CARE (BSC), IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) REFRACTORY TO STANDARD THERAPIES (RECOURSE)

Y. Shimada, Mamoru Ito, H. Lenz, 2014 .

Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer

A. Ohtsu, T. Yoshino, T. Doi, 2017, Clinical colorectal cancer.

Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.

I. Hyodo, J. Abbruzzese, S. Wadler, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

S. Yoshida, I. Hyodo, A. Ohtsu, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical impact of surveillance for head and neck cancer in patients with esophageal squamous cell carcinoma

K. Kaneko, T. Yano, Y. Oono, 2017, World journal of gastroenterology.

Treatment Strategy for Superficial Pharyngeal Squamous Cell Carcinoma Synchronously Combined with Esophageal Cancer

K. Kaneko, T. Yano, Y. Oono, 2012, Oncology.

Long-term outcome of transoral organ-preserving pharyngeal endoscopic resection for superficial pharyngeal cancer.

A. Yoshizawa, T. Yano, A. Ochiai, 2011, Gastrointestinal endoscopy.

Routine endoscopy using electronic endoscopes for gastric cancer diagnosis: retrospective study of inconsistencies between endoscopic and biopsy diagnoses.

H. Tajiri, A. Ohtsu, N. Boku, 2001, Cancer detection and prevention.

Association between aldehyde dehydrogenase gene polymorphisms and the phenomenon of field cancerization in patients with head and neck cancer.

S. Yoshida, H. Esumi, A. Ohtsu, 2002, Carcinogenesis.

Artificially Induced Epithelial-Mesenchymal Transition in Surgical Subjects: Its Implications in Clinical and Basic Cancer Research

Kazuhiko Aoyagi, Y. Tachimori, Teruhiko Yoshida, 2011, PloS one.

Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer

K. Kaneko, T. Yano, A. Ohtsu, 2016, Radiation Oncology.

OPTICAL/DIGITAL CHROMOENDOSCOPY DURING COLONOSCOPY USING NARROW‐BAND IMAGING SYSTEM

Hisao Tajiri, Yasushi Sano, H. Tajiri, 2005 .

Risk of multiple squamous cell carcinomas both in the esophagus and the head and neck region.

S. Yoshida, H. Esumi, A. Ohtsu, 2005, Carcinogenesis.

A new technique for endoscopic mucosal resection with an insulated-tip electrosurgical knife improves the completeness of resection of intramucosal gastric neoplasms.

Hisao Tajiri, Motoki Yoshida, Yasuo Hamamoto, 2002, Gastrointestinal endoscopy.

Patients' perception of the usefulness of a question prompt sheet for advanced cancer patients when deciding the initial treatment: a randomized, controlled trial

Y. Nishiwaki, A. Ohtsu, Y. Uchitomi, 2012, Psycho-oncology.

Causal relationships between esophageal squamous cell carcinoma and nephrotic syndrome.

K. Kaneko, A. Ohtsu, Hiroaki Ito, 2009, Internal medicine.

TREATMENT STRATEGIES FOR ESOPHAGEAL STRICTURE BEFORE OR AFTER CHEMORADIOTHERAPY FOR ADVANCED ESOPHAGEAL CANCER

S. Yoshida, A. Ohtsu, M. Muto, 2004 .

Advanced esophageal cancer with esophago-bronchial fistula successfully treated by chemoradiation therapy with additional endoscopic resection: a case report.

A. Ohtsu, N. Boku, S. Ishikura, 2002, Japanese journal of clinical oncology.

Self-expandable metallic stents for patients with recurrent esophageal carcinoma after failure of primary chemoradiotherapy.

S. Yoshida, Y. Shioyama, A. Ohtsu, 2001, Japanese journal of clinical oncology.

Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.

S. Yoshida, K. Kaneko, K. Muro, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma

A. Ohtsu, K. Chìn, Ken Kato, 2016, Cancer Chemotherapy and Pharmacology.

Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.

K. Kaneko, T. Yano, K. Nihei, 2011, Japanese journal of clinical oncology.

EMR as salvage treatment for patients with locoregional failure of definitive chemoradiotherapy for esophageal cancer.

S. Yoshida, A. Ohtsu, M. Muto, 2003, Gastrointestinal endoscopy.

Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.

Satoshi Morita, Yasuo Ohashi, Junichi Sakamoto, 2013, Journal of the National Cancer Institute.

Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials.

C. Fuchs, A. Barzi, A. Ohtsu, 2019, European journal of cancer.

Endoscopic submucosal dissection using a new scissors-type electrosurgical knife: a first-in-human feasibility study

K. Kaneko, T. Yano, Y. Oono, 2014, Endoscopy.

Diverse eastern and Western approaches to the management of gastric cancer.

A. Ohtsu, 2007, Gastrointestinal cancer research : GCR.

Disparities in gastric cancer chemotherapy between the East and West.

N. Saijo, S. Yoshida, A. Ohtsu, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ramucirumab for gastric cancer

A. Ohtsu, K. Shitara, 2015, Expert review of gastroenterology & hepatology.

Phase I trial of chemoradiotherapy with the combination of S‐1 plus cisplatin for patients with unresectable locally advanced squamous cell carcinoma of the head and neck

H. Mukai, A. Ohtsu, K. Matsuura, 2011, Cancer science.

Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407)

Y. Einaga, K. Tsuchihashi, H. Saya, 2017, Gastric Cancer.

Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients

T. Yamanaka, A. Ochiai, A. Ohtsu, 2015, Gastric Cancer.

Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma

A. Ochiai, A. Ohtsu, H. Fujii, 2015, Gastric Cancer.

Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study

E. Baba, A. Ohtsu, K. Chìn, 2012, Gastric Cancer.

A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial)

I. Hyodo, Y. Arai, A. Ohtsu, 2011, Gastric Cancer.

Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study

E. Baba, Y. Ohashi, A. Ohtsu, 2011, Gastric Cancer.

Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer

S. Yoshida, A. Ohtsu, F. Nagashima, 2006, Gastric Cancer.

Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer

A. Ohtsu, S. Tanabe, Y. Matsumura, 2003, British Journal of Cancer.

Clinicopathological, endoscopic, and molecular characteristics of the “skirt” – a new entity of lesions at the margin of laterally spreading tumors

K. Kaneko, T. Yano, Y. Oono, 2016, Endoscopy.

Tumor response and symptom palliation from RAINBOW, a phase 3 trial of ramucirumab plus paclitaxel in previously treated advanced gastric cancer.

J. Ajani, E. Van Cutsem, G. Bodoky, 2020, The oncologist.

Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan

Teruhiko Yoshida, N. Saijo, N. Kamatani, 2003 .

Phase I I S tudy o f a C ombination o f I rinotecan a nd C isplatin Against M etastatic G astric C ancer

I. Hyodo, A. Ohtsu, Y. Shimada, 1999 .

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer.

I. Hyodo, A. Ohtsu, Y. Shimada, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer.

M. Oka, Y. Shimada, H. Ono, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endoscopic balloon dilatation for benign fibrotic strictures after curative nonsurgical treatment for esophageal cancer

K. Kaneko, T. Yano, Y. Oono, 2012, Surgical Endoscopy.

A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors

A. Ohtsu, T. Yoshino, T. Doi, 2016, Cancer Chemotherapy and Pharmacology.

Phase I study of olaratumab in Japanese patients with advanced solid tumors

J. Nippgen, A. Ohtsu, T. Doi, 2014, Cancer science.

Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin.

S. Yoshida, I. Hyodo, A. Ohtsu, 2007, Japanese journal of clinical oncology.

Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin.

M. Ando, S. Yoshida, A. Ochiai, 2005, Japanese journal of clinical oncology.

Chemotherapy for metastatic gastric cancer: past, present, and future

A. Ohtsu, 2008, Journal of Gastroenterology.

Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein–Barr virus status in a large cohort of gastric cancer patients

A. Ochiai, A. Ohtsu, T. Yoshino, 2017, Gastric Cancer.

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial.

Y. Doki, K. Muro, A. Ohtsu, 2017, The Lancet. Oncology.

Detection of K‐ras gene mutations at codon 12 in the pancreatic juice of patients with intraductal papillary mucinous tumors of the pancreas

S. Yoshida, A. Ohtsu, H. Kondo, 1997, Cancer.

Application of a Combination of a Knowledge-Based Algorithm and 2-Stage Screening to Hypothesis-Free Genomic Data on Irinotecan-Treated Patients for Identification of a Candidate Single Nucleotide Polymorphism Related to an Adverse Effect

Teruhiko Yoshida, N. Saijo, H. Sakamoto, 2014, PloS one.

Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data.

Teruhiko Yoshida, H. Sakamoto, A. Ohtsu, 2013, Journal of bioscience and bioengineering.

Overview of adjuvant therapy for resected gastric cancer: differences in Japan and the United States.

A. Ohtsu, M. Sasako, 2005, Seminars in oncology.

Chemotherapy for Advanced Unresectable Gastric Cancer

A. Ohtsu, 2005 .

Clinical significance of magnetic resonance cholangiopancreatography for the diagnosis of cystic tumor of the pancreas compared with endoscopic retrograde cholangiopancreatography and computed tomography.

H. Tajiri, N. Moriyama, S. Yoshida, 1999, Japanese Journal of Clinical Oncology.

Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma

H. Matsumoto, A. Ohtsu, T. Yoshino, 2018, ESMO Open.

Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors

M. Kodaira, K. Yonemori, K. Tamura, 2015, Cancer Chemotherapy and Pharmacology.

A phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody “EMD72000 (Matuzumab)” administered weekly in Japanese patients with advanced solid tumors; safety, PK and PD results of skin biopsies

N. Saijo, F. Rojo, A. Ohtsu, 2005 .

Clinicopathological studies on coexisting gastric malignant lymphoma and gastric adenocarcinoma: report of four cases and review of the Japanese literature.

S. Yoshida, Y. Matsuno, H. Ono, 1997, Japanese journal of clinical oncology.

Impaired mental health among the bereaved spouses of cancer patients

K. Nagai, A. Ohtsu, T. Akechi, 2013, Psycho-oncology.

Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population.

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2008, Drug metabolism and pharmacokinetics.

Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences

Teruhiko Yoshida, N. Saijo, N. Kamatani, 2007, Journal of Human Genetics.

Discrepancies between the gene expression, protein expression, and enzymatic activity of thymidylate synthase and dihydropyrimidine dehydrogenase in human gastrointestinal cancers and adjacent normal mucosa.

M. Fukushima, S. Yoshida, A. Ochiai, 2001, International journal of oncology.

Relationship between Pulmonary Adverse Events and Everolimus Exposure in Japanese and Non-Japanese Patients: A Meta-Analysis of Oncology Trials

A. Ravaud, S. Noguchi, A. Ohtsu, 2017, Oncology.

Genetic variations of the AHR gene encoding aryl hydrocarbon receptor in a Japanese population.

Teruhiko Yoshida, N. Saijo, N. Kamatani, 2004, Drug metabolism and pharmacokinetics.

A model chemosensitivity test examining apoptosis in small specimens of gastric cancer

S. Yoshida, A. Ohtsu, N. Boku, 2000, Gastric Cancer.

Functional analysis of four naturally occurring variants of human constitutive androstane receptor.

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2005, Molecular genetics and metabolism.

A novel gene–protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity

A. Ochiai, A. Ohtsu, H. Nitta, 2015, Gastric Cancer.

Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106).

A. Ohtsu, K. Shirao, T. Doi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II study of best-available 5-fluorouracil (5-FU) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-FU-containing regimens (JCOG0407).

Y. Shimada, A. Ohtsu, Y. Hamamoto, 2010 .

Impact of dihydropyrimidine dehydrogenase status of biopsy specimens on efficacy of irinotecan plus cisplatin, S-1, or 5-FU as first-line treatment of advanced gastric cancer patients in JCOG9912.

A. Ohtsu, N. Boku, J. Nasu, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial.

S. Yoshida, I. Hyodo, A. Ohtsu, 2004, Japanese journal of clinical oncology.

Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population

Teruhiko Yoshida, N. Saijo, Y. Goto, 2004, Human mutation.

Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28

Teruhiko Yoshida, H. Ohmatsu, N. Saijo, 2007, Pharmacogenetics and genomics.

Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2008, Cancer Chemotherapy and Pharmacology.

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.

M. Shah, J. Tabernero, Yoon-Koo Kang, 2018, The Lancet. Oncology.

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.

J. Ajani, M. Shah, E. Van Cutsem, 2017, The Lancet. Oncology.

Phase I trial of pimasertib monotherapy in Japanese patients with solid tumors and those with hepatocellular carcinoma

A. Schueler, A. Ohtsu, M. Ikeda, 2019, Cancer Chemotherapy and Pharmacology.

Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan.

Y. Sugiyama, Teruhiko Yoshida, N. Saijo, 2003, Drug metabolism and pharmacokinetics.

Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer

Y. Doki, K. Muro, A. Ohtsu, 2020, Cancer science.

Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum.

P. Johnston, H. Tajiri, S. Yoshida, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905-DI)

K. Muro, A. Ohtsu, Ken Kato, 2014, Esophagus.

Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases

T. Yano, A. Ohtsu, T. Yoshino, 2011, Cancer Chemotherapy and Pharmacology.

Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I–II1, diffuse large B‐cell lymphoma of the stomach

M. Taniwaki, T. Yoshino, Y. Tamaki, 2005, Cancer science.

Phase I dose-finding study of golvatinib (E7050), a c-Met and Eph receptor targeted multi-kinase inhibitor, administered orally BID to patients with advanced solid tumors.

A. Ohtsu, T. Yoshino, M. Tahara, 2012 .

Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial

M. Shah, J. Tabernero, Yoon-Koo Kang, 2022, Gastric Cancer.

Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: An international phase III study (JACOB).

J. Tabernero, Yoon-Koo Kang, A. Ohtsu, 2013 .

Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer

A. Ohtsu, Y. Tanigawara, Y. Shimada, 2008, British Journal of Cancer.

Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial

S. Nomura, A. Sato, A. Ohtsu, 2021, Nature Medicine.

Pertuzumab plus trastuzumab and real-world standard of care (SOC) for patients (pts) with treatment refractory metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) confirmed by tumor tissue or ctDNA analysis (TRIUMPH, EPOC1602).

S. Nomura, A. Sato, A. Ohtsu, 2021 .

Onset of neutropenia as an indicator of treatment response in the randomized phase II of TAS-102 vs placebo in Japanese patients with metastatic colorectal cancer (Study J003-10040030).

N. Sugimoto, K. Muro, A. Ohtsu, 2016 .

Survival analysis according to disease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer.

M. Shah, Y. Bang, E. Van Cutsem, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Naotoshi Sugimoto, Yasuhiro Shimada, David Ferry, 2014, The Lancet. Oncology.

Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study.

J. Ajani, E. Van Cutsem, G. Bodoky, 2020, European journal of cancer.

Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer

J. Ajani, C. Fuchs, E. Van Cutsem, 2017, Molecular Cancer Therapeutics.

Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer.

J. Ajani, C. Fuchs, J. Tabernero, 2015 .

1423MO End-of-study analysis from JACOB: A phase III study of pertuzumab (P) + trastuzumab (H) and chemotherapy (CT) in HER2-positive metastatic gastric or gastro-esophageal junction cancer (mGC/GEJC)

M. Shah, J. Tabernero, A. Ohtsu, 2020 .

Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer

M. Shah, Yoon-Koo Kang, M. Alsina, 2019, Cancer Chemotherapy and Pharmacology.

Pharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC).

M. Shah, J. Tabernero, Yoon-Koo Kang, 2018 .

O-007Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study

J. Ajani, G. Bodoky, Z. Wainberg, 2016 .

Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303)

S. Nomura, A. Sato, K. Muro, 2017, Esophagus.

LBA13PHASE III RECOURSE TRIAL OF TAS-102 VS. PLACEBO, WITH BEST SUPPORTIVE CARE (BSC), IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) REFRACTORY TO STANDARD THERAPIES

Y. Shimada, J. Tabernero, B. Tran, 2014 .

Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer

A. Ohtsu, Y. Hamamoto, T. Satoh, 2012, Cancer Chemotherapy and Pharmacology.

O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma

C. Fuchs, M. Mandalà, C. Shih, 2020 .

PD-014Final survival results and onset of neutropenia as an indicator of therapeutic effect in phase 2 of TAS-102 vs placebo with metastatic colorectal cancer (J003-10040030)

N. Sugimoto, K. Muro, A. Ohtsu, 2016 .

An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer.

Y. Shimada, R. Kanamaru, K. Muro, 1998, American journal of clinical oncology.

The role of chemotherapy in the current treatment of gastric cancer

D. Haller, A. Ohtsu, E. Cutsem, 2002, Gastric Cancer.

AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC).

M. Shah, E. Van Cutsem, A. Ohtsu, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECOURSE trial.

H. Lenz, J. Tabernero, B. Tran, 2016 .

Submucosal tumor appearance is a useful endoscopic predictor of early primary-site recurrence after definitive chemoradiotherapy for esophageal squamous cell carcinoma.

S. Yoshida, T. Yano, K. Nihei, 2011, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Inhibition of Colony Formation of Drug‐resistant Human Tumor Cell Lines by Combinations of Interleukin‐2‐activated Killer Cells and Antitumor Drugs

N. Saijo, Y. Ohe, Y. Fujiwara, 1989, Japanese journal of cancer research : Gann.

Efficacy of surgery after successful chemotherapy for advanced gastric cancer

S. Yoshida, A. Ohtsu, M. Kurihara, 1998, International Journal of Clinical Oncology.

Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice

S. Yoshida, A. Ohtsu, M. Muto, 2001, Gastric Cancer.

Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG).

A. Ohtsu, M. Kurihara, Y. Shimada, 1994, European journal of cancer.

A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial.

S. Yoshida, I. Hyodo, A. Ohtsu, 2008, Japanese journal of clinical oncology.

Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer.

M. Fukushima, A. Ochiai, A. Ohtsu, 2000, International journal of oncology.

KEYNOTE-585: Phase 3 study of chemotherapy (chemo) + pembrolizumab (pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer.

T. Yoshikawa, Laura H. Tang, Y. Bang, 2018 .

LBA24Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration

T. Yamanaka, Masato Nakamura, J. Sakamoto, 2017 .

Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.

Y. Bang, C. Fuchs, E. Van Cutsem, 2020 .

Clinical Cancer esearch cer Therapy : Clinical se I Study of NK 012 , a Novel SN-38 – Incorporating Micellar R oparticle , in Adult Patients with Solid Tumors

A. Ohtsu, Ken Kato, Y. Matsumura, 2010 .

Haplotype structures of the UGT1A gene complex in a Japanese population

N. Saijo, N. Kamatani, K. Kubota, 2006, The Pharmacogenomics Journal.

Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil.

S. Yoshida, J. Fujimoto, A. Ohtsu, 2004, Oncology reports.

Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1.

J. Ajani, Y. Bang, E. Van Cutsem, 2012, Journal of Clinical Oncology.

Future perspectives of chemotherapy for advanced gastric cancer

A. Ohtsu, T. Yoshino, M. Tahara, 2009, Gastric Cancer.

Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205)

Y. Einaga, K. Tsuchihashi, H. Saya, 2017, Gastric Cancer.

Onset of neutropenia as an indicator of treatment response in the phase 3 RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo in patients with metastatic colorectal cancer.

H. Lenz, B. Tran, R. Mayer, 2017 .

Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology Group Trials JCOG9205 and JCOG9912

A. Ohtsu, Ken Kato, Y. Shimada, 2013, Gastric Cancer.

Small cell carcinoma of the esophagus with an esophago-mediastinal fistula successfully treated by chemoradiation therapy and intubation: a case report.

K. Muro, A. Ohtsu, N. Boku, 1993, Japanese journal of clinical oncology.

Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors

A. Ohtsu, Ken Kobayashi, I. Okamoto, 2009, Japanese journal of clinical oncology.

Phase I Clinical and Pharmacokinetic Study of RAD 001 ( Everolimus ) Administered Daily to Japanese Patients with Advanced Solid Tumors

A. Ohtsu, Ken Kobayashi, I. Okamoto, 2009 .

Fourteen novel genetic variations and haplotype structures of the TYMS gene encoding human thymidylate synthase (TS).

Teruhiko Yoshida, N. Saijo, N. Kamatani, 2006, Drug metabolism and pharmacokinetics.

Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck.

A. Ohtsu, K. Matsuura, M. Tahara, 2012, Japanese journal of clinical oncology.

A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC).

J. Ajani, M. Shah, Yoon-Koo Kang, 2016 .

NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis

A. Ohtsu, T. Hamaguchi, Y. Shimada, 2017, Cancer Chemotherapy and Pharmacology.

Interim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer.

Jianming Xu, K. Yeh, A. Ohtsu, 2010 .

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

Y. Bang, K. Yeh, A. Ohtsu, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract C6: Phase 1 study of conatumumab (AMG 655), a proapoptotic death receptor‐5 agonist antibody, in Japanese patients with advanced solid tumors

A. Ohtsu, H. Murakami, N. Yamamoto, 2009 .

Expression of HER2 in gastric cancer: Comparison between protein expression and gene amplification using a new commercial kit.

A. Ochiai, A. Ohtsu, T. Doi, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemoradiotherapy for squamous cell carcinoma of the anus: the same histology but different story?

A. Ohtsu, 2007 .

Three novel single nucleotide polymorphisms in UGT1A9.

Teruhiko Yoshida, N. Saijo, A. Ohtsu, 2003, Drug metabolism and pharmacokinetics.

Three novel single nucleotide polymorphisms in UGT1A10.

Teruhiko Yoshida, H. Ohmatsu, R. Kakinuma, 2002, Drug metabolism and pharmacokinetics.

Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy

S. Yoshida, T. Yano, T. Sugiyama, 2007, Journal of Gastroenterology.

Relationship between expression of vascular endothelial growth factor in tumor tissue from gastric cancers and chemotherapy effects: comparison between S-1 alone and the combination of S-1 plus CDDP.

A. Ohtsu, W. Koizumi, K. Shirao, 2007, Japanese journal of clinical oncology.

Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey

Y. Sano, S. Yoshida, T. Yano, 2003, Gastric Cancer.

Accuracy of Capillary Pattern Classification Using NBI Magnification for Diagnosis of Colorectal Lesions

Y. Sano, K. Kaneko, H. Ikematsu, 2008 .

Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant

Teruhiko Yoshida, N. Saijo, K. Muro, 2012, Immunogenetics.

Epstein–Barr virus involvement is a predictive factor for the resistance to chemoradiotherapy of gastric diffuse large B‐cell lymphoma

T. Yoshino, A. Ochiai, Y. Matsuno, 2006, Cancer science.

6005 ORAL A Multicenter, Randomized, Double-blind, Phase II Study of TAS-102 (A) Plus Best Supportive Care (BSC) Versus Placebo (P) Plus BSC in Patients (pts) With Chemotherapy-refractory Metastatic Colorectal Cancer (mCRC)

K. Muro, A. Ohtsu, H. Baba, 2011 .

Joint United States of America (USA)/Japan study of UFT (uracil and tegafur) plus leucovorin (LV) in patients (pts) with metastatic colorectal cancer (CRC)

I. Hyodo, J. Abbruzzese, A. Ohtsu, 2001 .

Twenty-six novel single nucleotide polymorphisms and their frequencies of the NR1I3 (CAR) gene in a Japanese population.

Teruhiko Yoshida, N. Saijo, Y. Goto, 2003, Drug metabolism and pharmacokinetics.

Carcinoma coexisting with esophageal leiomyoma.

N. Kanomata, Y. Sano, S. Yoshida, 2002, Gastrointestinal endoscopy.

Genetic polymorphisms of FCGRT encoding FcRn in a Japanese population and their functional analysis.

Teruhiko Yoshida, N. Saijo, K. Muro, 2010, Drug metabolism and pharmacokinetics.

Verrucous carcinoma of the esophagus completely resected by endoscopy.

H. Tajiri, S. Yoshida, A. Ohtsu, 2000 .

Verrucous carcinoma of the esophagus completely resected by endoscopy

H. Tajiri, S. Yoshida, A. Ohtsu, 2000, American Journal of Gastroenterology.

Usefulness of endoscopic radial incision and cutting method for refractory esophagogastric anastomotic stricture (with video).

T. Yano, A. Ohtsu, T. Chiba, 2012, Gastrointestinal endoscopy.

FUNCTIONAL CHARACTERIZATION OF THREE NATURALLY OCCURRING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE CES2 GENE ENCODING CARBOXYLESTERASE 2 (HCE-2)

Teruhiko Yoshida, N. Saijo, A. Ohtsu, 2005, Drug Metabolism and Disposition.

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kazuhiro Yoshida, A. Benson, Y. Bang, 2018, The Lancet.

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial

P. Philip, M. Shah, Y. Bang, 2018, JAMA oncology.

A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer

A. Ohtsu, Ken Kato, H. Minami, 2013, Gastric Cancer.

Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials

L. Rubinstein, A. Ohtsu, T. Yoshino, 2015, Gastric Cancer.

Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.

J. Baselga, E. Van Cutsem, F. Rojo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer

J. Ajani, M. Shah, E. Van Cutsem, 2019, Gastric Cancer.

mTOR as a therapeutic target in patients with gastric cancer

M. Ducreux, A. Ohtsu, S. Al-Batran, 2012, International journal of cancer.

Phase 2 study of nilotinib as third‐line therapy for patients with gastrointestinal stromal tumor

Y. Kakeji, T. Nishida, A. Ohtsu, 2011, Cancer.

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.

M. Shah, E. Van Cutsem, Yoon-Koo Kang, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience

A. Ohtsu, T. Yoshino, T. Doi, 2015, Investigational New Drugs.

A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites

H. Matsumoto, A. Ohtsu, T. Yoshino, 2018, BMC Cancer.

Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm

M. Shah, E. Van Cutsem, Yoon-Koo Kang, 2017, Gastric Cancer.

Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data

C. Fuchs, E. Van Cutsem, H. Safran, 2017, Journal of gastric cancer.

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma†

Y. Shimada, E. Van Cutsem, N. Sugimoto, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer

N. Sugimoto, K. Muro, A. Ohtsu, 2016, Gastric Cancer.

32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part Two

Linda Z Sun, T. Yoshikawa, Laura H. Tang, 2017, Journal of Immunotherapy for Cancer.

Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma

S. Nomura, A. Ochiai, A. Ohtsu, 2016, Oncotarget.

Growth patterns and genetic changes of colorectal carcinoma.

K. Kaneko, A. Ohtsu, N. Boku, 1998, Japanese journal of clinical oncology.

Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

J. Ajani, Y. Bang, E. Van Cutsem, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma

A. Ochiai, A. Ohtsu, H. Daiko, 2017, BMC Cancer.

The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010.

R. Labianca, D. Kerr, K. Haustermans, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer

S. Kobayashi, S. Matsumoto, K. Yoh, 2021, Nature.

Detection of point mutations in the K‐ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma

S. Yoshida, Y. Shimosato, A. Ohtsu, 1994, Cancer.

A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors

M. Osada, A. Ohtsu, T. Yoshino, 2016, Cancer Chemotherapy and Pharmacology.

Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies

R. Yamashita, E. Oki, T. Yamanaka, 2020, Nature Medicine.

Large-scale comprehensive immunohistochemical biomarker analyses in esophageal squamous cell carcinoma

S. Nomura, A. Ochiai, A. Ohtsu, 2017, Journal of Cancer Research and Clinical Oncology.

Therapeutic landscape and future direction of metastatic colorectal cancer

A. Ohtsu, T. Yoshino, H. Bando, 2023, Nature Reviews Gastroenterology & Hepatology.

Title Report on the use of non-clinical studies in the regulatoryevaluation of oncology drugs

T. Naoe, T. Ochiya, Y. Sugiyama, 2019 .

Report on the use of non‐clinical studies in the regulatory evaluation of oncology drugs

T. Naoe, T. Ochiya, Y. Sugiyama, 2016, Cancer science.

Characterization of the large‐scale Japanese patient‐derived xenograft (J‐PDX) library

Y. Yatabe, H. Mano, A. Ochiai, 2021, Cancer science.

Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy

R. Yamashita, S. Mimaki, K. Tsuchihara, 2019, BMC Cancer.

Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies

R. Yamashita, E. Oki, T. Yamanaka, 2020, Nature Medicine.

Fluorescent diagnosis of experimental gastric cancer using a tumor-localizing photosensitizer.

H. Tajiri, A. Ohtsu, N. Boku, 1997, Cancer letters.

Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma

A. Ochiai, A. Ohtsu, H. Daiko, 2019, British Journal of Cancer.

Establishment of Novel Gastric Cancer Patient-Derived Xenografts and Cell Lines: Pathological Comparison between Primary Tumor, Patient-Derived, and Cell-Line Derived Xenografts

A. Ochiai, H. Katai, A. Ohtsu, 2019, Cells.

Non-surgical approach to small cell carcinoma of the esophagus: does this rare disease have the same tumor behavior as SCLC?

T. Yano, K. Nihei, A. Ohtsu, 2012, International Journal of Clinical Oncology.

Gastric Cancer Working Group report.

M. Inoue, A. Ohtsu, Jaw-Town Lin, 2010, Japanese journal of clinical oncology.

Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009.

R. Labianca, J. Berlin, K. Haustermans, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer.

I. Hyodo, K. Muro, A. Ohtsu, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan.

Teruhiko Yoshida, N. Saijo, N. Kamatani, 2003, Pharmacogenetics.

UGT1A1 Haplotypes Associated with Reduced Glucuronidation and Increased Serum Bilirubin in Irinotecan‐administered Japanese Patients with Cancer

Kazuo Komamura, Naoyuki Kamatani, Noriko Katori, 2004, Clinical pharmacology and therapeutics.

12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study.

E. Oki, T. Yamanaka, Y. Ohashi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Nationwide Cancer Genome Screening Project for Gastrointestinal Cancer in Japan (GI-SCREEN): MSI-status and cancer-related genome alterations in advanced colorectal cancer (CRC)—GI-SCREEN 2013-01-CRC sub-study.

A. Ohtsu, T. Kudo, Yoshiyuki Yamamoto, 2016 .

Nonplatinum‐based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma

A. Ohtsu, M. Tahara, H. Minami, 2008, Cancer.

Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population.

Teruhiko Yoshida, N. Saijo, N. Kamatani, 2006, Drug metabolism and pharmacokinetics.

Close Association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 Haplotype and Its Apparent Influence on 7-Ethyl-10-hydroxycamptothecin (SN-38) Glucuronidation in Japanese

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2009, Drug Metabolism And Disposition.

Functional Characterization of Human UDP-Glucuronosyltransferase 1A9 Variant, D256N, Found in Japanese Cancer Patients

Teruhiko Yoshida, N. Saijo, A. Ohtsu, 2003, Journal of Pharmacology and Experimental Therapeutics.

Prophylactic steroid administration for strictures after endoscopic resection of large superficial esophageal squamous cell carcinoma

K. Kaneko, T. Yano, Y. Oono, 2016, Endoscopy International Open.

Guidelines for diagnosis and treatment of carcinoma of the esophagus

Y. Nishimura, H. Kuwano, H. Matsubara, 2008, Esophagus.

Efficacy of Preventive Endoscopic Balloon Dilation for Esophageal Stricture After Endoscopic Resection

T. Yano, A. Ohtsu, T. Chiba, 2011, Journal of clinical gastroenterology.

Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma.

S. Yoshida, T. Yano, K. Nihei, 2008, Endoscopy.

Guidelines for Diagnosis and Treatment of Carcinoma of the Esophagus April 2007 edition: part I Edited by the Japan Esophageal Society

Y. Nishimura, H. Kuwano, H. Matsubara, 2008, Esophagus.

Endoscopic mucosal resection in the stomach using the insulated-tip needle-knife.

L. Gossner, S. Yoshida, A. Ohtsu, 2005, Endoscopy.

Local recurrence of squamous-cell carcinoma of the esophagus after EMR.

S. Yoshida, A. Ohtsu, M. Muto, 2005, Gastrointestinal endoscopy.

Salvage photodynamic therapy for local failure after chemoradiotherapy for esophageal squamous cell carcinoma.

K. Kaneko, T. Yano, S. Nomura, 2016, Gastrointestinal endoscopy.

Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer

K. Kaneko, T. Yano, A. Ohtsu, 2016, Radiation oncology.

Photodynamic therapy as salvage treatment for local failure after chemoradiotherapy in patients with esophageal squamous cell carcinoma: A phase II study

K. Kaneko, T. Yano, A. Ohtsu, 2012, International journal of cancer.

Implantation of self-expanding metallic stent for patients with malignant stricture after failure of definitive chemoradiotherapy for T3 or T4 esophageal squamous cell carcinomas.

K. Kaneko, A. Ohtsu, Hiroaki Ito, 2002, Hepato-gastroenterology.

A newly developed bipolar-current needle-knife for endoscopic submucosal dissection of large colorectal tumors.

Y. Sano, Yutaka Saito, T. Fujimori, 2006, Endoscopy.

SCRUM‐Japan GI‐SCREEN and MONSTAR‐SCREEN: Path to the realization of biomarker‐guided precision oncology in advanced solid tumors

K. Tsuchihara, A. Ohtsu, T. Yoshino, 2021, Cancer science.

Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial).

T. Kawaguchi, J. Sakamoto, F. Matsuda, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.

T. Kohno, Y. Ohe, S. Nomura, 2017, The Lancet. Respiratory medicine.

Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate

T. Nishida, K. Muro, A. Ohtsu, 2010, Investigational New Drugs.

Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202)

S. Hirota, T. Nishida, T. Sugiyama, 2008, International Journal of Clinical Oncology.

Expression of Integrin α3 in Gastric and Colorectal Cancers: Its Relation to Wall Contraction and Mode of Invasion

S. Yoshida, A. Ohtsu, Y. Oda, 1995, Japanese journal of cancer research : Gann.

Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer

K. Muro, A. Ohtsu, T. Yoshino, 2013, Cancer Chemotherapy and Pharmacology.

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer

T. Yamanaka, A. Ohtsu, T. Yoshino, 2015, BMC Cancer.

Long-Term T oxicity A fter D efinitive C hemoradiotherap y f or Squamous C ell C arcinoma o f t he T horacic E sophagus

S. Yoshida, K. Nihei, A. Ohtsu, 2003 .

KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab

K. Kaneko, H. Esumi, A. Ochiai, 2011, British Journal of Cancer.

Guidelines for clinical evaluation of anti‐cancer drugs

Toshio Shimizu, K. Nishio, A. Ohtsu, 2021, Cancer science.

Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer

T. Akimoto, A. Ohtsu, T. Yoshino, 2019, Gastric Cancer.

Macroscopic typing with wall stricture sign may reflect tumor behaviors of advanced colorectal cancers

H. Tajiri, S. Yoshida, A. Ochiai, 2001, Journal of Gastroenterology.

Streptococcus milleri infection and pericardial abscess associated with esophageal carcinoma: report of two cases.

H. Tajiri, S. Yoshida, A. Ohtsu, 1999, Hepato-gastroenterology.

Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.

D. Tu, J. Zalcberg, J. Simes, 2018, The lancet. Gastroenterology & hepatology.

Enhanced antitumor effect of anti-tissue factor antibody-conjugated epirubicin-incorporating micelles in xenograft models

I. Hyodo, A. Ohtsu, Yoshiyuki Yamamoto, 2015, Cancer science.

Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients

S. Hirota, Masakazu Yamamoto, Y. Kakeji, 2013, International Journal of Clinical Oncology.

Gene expression profiling to predict recurrence of advanced squamous cell carcinoma of the tongue: discovery and external validation

S. Nomura, A. Ohtsu, M. Tahara, 2017, Oncotarget.

Haplotypes and a Novel Defective Allele of CES2 Found in a Japanese Population

Teruhiko Yoshida, N. Saijo, N. Kamatani, 2007, Drug Metabolism and Disposition.

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.

M. Shah, E. Van Cutsem, Yoon-Koo Kang, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions.

I. Hyodo, A. Ohtsu, T. Taguchi, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).

K. Muro, A. Ohtsu, Ken Kato, 2011, International journal of radiation oncology, biology, physics.

[Current Status and Future Perspectives of SCRUM-Japan].

K. Goto, K. Tsuchihara, A. Ohtsu, 2017, Gan to kagaku ryoho. Cancer & chemotherapy.

Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2010, British journal of clinical pharmacology.

A phase II study of doxifluridine in elderly patients with advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG 9410).

S. Yoshida, A. Ohtsu, W. Koizumi, 2002, Japanese journal of clinical oncology.

Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations

E. Van Cutsem, A. Grothey, A. Ohtsu, 2014, Investigational New Drugs.

Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors

M. Robson, A. Ohtsu, Y. Ando, 2014, Cancer science.

Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma.

A. Ohtsu, Ling Gao, T. Yoshino, 2015, Anticancer research.

Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors

J. Watanabe, A. Ohtsu, H. Murakami, 2012, Cancer Chemotherapy and Pharmacology.

The Differential Diagnosis of Malignant Lymphoma and Reactive Lymphoreticular Hyperplasia of the Stomach Using Endoscopic Ultrasonography

S. Yoshida, A. Ochiai, A. Ohtsu, 1994 .

Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.

T. Yano, A. Ochiai, A. Ohtsu, 2006, Oncology reports.

Induction chemotherapy with docetaxel, cisplatin and S-1 followed by proton beam therapy concurrent with cisplatin in patients with T4b nasal and sinonasal malignancies.

A. Ohtsu, T. Yoshino, M. Tahara, 2012, Japanese journal of clinical oncology.

Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer

S. Yoshida, A. Ohtsu, Y. Shimada, 2000, Gastric Cancer.

Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07)

Y. Doki, K. Muro, A. Ohtsu, 2021, Esophagus.

An early phase II study of etoposide (VP-16) in advanced gastric cancer.

Y. Shimada, A. Ohtsu, K. Hosokawa, 1996, Japanese journal of clinical oncology.

Oxaliplatin-Based Adjuvant Chemotherapy Duration (3 vs. 6 Months) for High-Risk Stage II Colon Cancer: The Randomized Phase 3 ACHIEVE-2 Trial.

T. Rikiyama, E. Oki, T. Yamanaka, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Gastrointestinal Perforation and Fistula Formation in 5 Patients With Colorectal Cancer During Treatment With Regorafenib

A. Ohtsu, T. Yoshino, T. Doi, 2017, Clinical colorectal cancer.

Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer.

T. Ushijima, A. Ochiai, S. Yamashita, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of the human anti‐activin receptor‐like kinase 1 antibody PF‐03446962 in Asian patients with advanced solid tumors

Y. Bang, K. Yoh, A. Ohtsu, 2016, Cancer medicine.

Functional characterization of wild-type and variant (T202I and M59I) human UDP-glucuronosyltransferase 1A10.

Teruhiko Yoshida, N. Saijo, A. Ohtsu, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Efficacy of chemoradiotherapy on pain relief in patients with intrapelvic recurrence of rectal cancer.

K. Nihei, A. Ohtsu, N. Boku, 2003, Japanese journal of clinical oncology.

Pulmonary tumor thrombotic microangiopathy associated with esophageal squamous cell carcinoma.

T. Sugiyama, A. Ohtsu, T. Yoshino, 2011, Internal medicine.

Association of aldehyde dehydrogenase 2gene polymorphism with multiple oesophageal dysplasia in head and neck cancer patients

S. Yoshida, H. Esumi, A. Ohtsu, 2000, Gut.

Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients.

K. Kaneko, S. Nomura, A. Ochiai, 2015, Japanese journal of clinical oncology.

A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer

A. Ohtsu, T. Yoshino, T. Doi, 2012, Investigational New Drugs.

Retrospective study of hyponatremia in gastric cancer patients treated with a combination chemotherapy of 5-fluorouracil and cisplatin: a possible warning sign of severe hematological toxicities?

A. Ohtsu, M. Muto, S. Yoshida, 2001, Japanese journal of clinical oncology.

Clinicopathological differences between colonic and rectal carcinomas: are they based on the same mechanism of carcinogenesis?

H. Tajiri, S. Yoshida, A. Ochiai, 1999, Gut.

Depressed-type (0-IIc) colorectal neoplasm in patients with family history of first-degree relatives with colorectal cancer: A cross-sectional study.

Y. Sano, S. Yoshida, A. Ohtsu, 2006, World journal of gastroenterology.

S1557: Efficacy of Capillary Pattern Type IIIA/IIIB by Magnifying Narrow Band Imaging for Estimating Depth of Invasion of Early Colorectal Neoplasms

Y. Sano, K. Kaneko, T. Yano, 2010 .

Magnifying narrow-band imaging versus magnifying white-light imaging for the differential diagnosis of gastric small depressive lesions: a prospective study.

Y. Sano, T. Yano, A. Ohtsu, 2010, Gastrointestinal endoscopy.

NARROW‐BAND IMAGING COMBINED WITH MAGNIFIED ENDOSCOPY FOR CANCER AT THE HEAD AND NECK REGION

Y. Sano, S. Yoshida, A. Ohtsu, 2005 .

Correlation Between the Depth of Invasion and Hardness of Resected Gastric Carcinoma Specimens Using a New Ultrasound Tactile Sensor

H. Tajiri, S. Yoshida, A. Ohtsu, 1998 .

“Para‐lesional” Saline Injection Method for Assessment of Small Gastric Cancers by Endoscopic Ultrasonography

H. Tajiri, S. Yoshida, K. Kaneko, 1996 .

Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912.

A. Ohtsu, W. Koizumi, T. Yoshino, 2014, The oncologist.

Genetic polymorphisms of UGT1A6 in a Japanese population.

Teruhiko Yoshida, N. Saijo, N. Kamatani, 2005, Drug metabolism and pharmacokinetics.

Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106).

A. Ohtsu, Y. Hamamoto, A. Takashima, 2013, Japanese Journal of Clinical Oncology.

Randomized Phase III Study of 5-Fluorouracil Continuous Infusion vs . Sequential Methotrexate and 5-Fluorouracil Therapy in Far Advanced Gastric Cancer with Peritoneal Metastasis ( JCOG 0106 )

A. Ohtsu, Y. Hamamoto, A. Takashima, 2013 .

A phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in Japanese patients with gastrointestinal (GI) cancer

A. Ohtsu, T. Hamaguchi, K. Shirao, 2008 .

A Retrospective Study of Definitive Chemoradiotherapy for Elderly Patients With Esophageal Cancer

T. Yano, K. Nihei, A. Ohtsu, 2007, American journal of clinical oncology.

Psychological states and coping strategies after bereavement among spouses of cancer patients: a quantitative study in Japan

K. Nagai, A. Ohtsu, Y. Uchitomi, 2012, Supportive Care in Cancer.

Concurrent chemoradiotherapy for esophageal carcinoma patients with malignant fistulae

H. Tajiri, S. Yoshida, K. Muro, 1999, Cancer.

Treatment for locally advanced esophageal carcinoma complicated by fistulas: Case report

H. Tajiri, S. Yoshida, K. Muro, 1996, International Journal of Clinical Oncology.

A Case of Descending Necrotizing MediastinitisPenetrating to the Esophagus

A. Ohtsu, H. Tokano, K. Kitamura, 2010, Journal of rural medicine : JRM.

Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis

E. Van Cutsem, J. Tabernero, R. Mayer, 2020, ESMO Open.

Early clinical outcomes of anal squamous cell carcinoma treated with concurrent chemoradiotherapy with 5-Fluorouracil plus mitomycin C in Japanese patients: experience at a single institution.

K. Kaneko, H. Ikematsu, A. Ohtsu, 2012, Japanese journal of clinical oncology.

Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

Y. Bang, C. Fuchs, E. Van Cutsem, 2021, Gastric Cancer.

Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery

T. Fujita, A. Ohtsu, H. Daiko, 2016, Journal of surgical oncology.

Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer

S. Oh, Keun-Wook Lee, K. Muro, 2016, Journal of gastroenterology and hepatology.

KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer.

T. Yoshikawa, Laura H. Tang, Y. Bang, 2019, Future oncology.

Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

M. Shah, E. Van Cutsem, Z. Wainberg, 2021, The oncologist.

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

A. Ohtsu, T. Yoshino, T. Kuwata, 2019, Journal of Immunotherapy for Cancer.

Preliminary safety data from KEYNOTE-059: Pembrolizumab plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer.

Y. Bang, C. Fuchs, J. Tabernero, 2016 .

Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program

R. Yamashita, E. Oki, K. Tsuchihara, 2023, JCO precision oncology.

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial).

Kazuhiro Yoshida, Takao Takahashi, K. Muro, 2015, European journal of cancer.

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study

Yutaka Suzuki, T. Yamanaka, S. Nomura, 2017, British Journal of Cancer.

Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit

T. Yamanaka, K. Tsuchihara, A. Ohtsu, 2013, BMC Cancer.

Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus.

S. Yoshida, A. Ochiai, A. Ohtsu, 2003, International journal of radiation oncology, biology, physics.

Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial)

J. Sakamoto, K. Goto, A. Ohtsu, 2015, Cancer Chemotherapy and Pharmacology.

Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study

H. Tajiri, Y. Sano, S. Yoshida, 2001, Gastric Cancer.

T. Yamanaka, S. Nomura, H. Esumi, 2017, British Journal of Cancer.

Prognostic value of neutrophil-to-lymphocyte ratio (NLR) on overall survival (OS), progression free survival (PFS) and disease control rate (DCR) in patients with metastatic colorectal cancer (mCRC) from the RECOURSE study.

R. Mayer, A. Ohtsu, N. Amellal, 2018 .

Erratum to: Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study

E. Baba, A. Ohtsu, Y. Hamamoto, 2012, Gastric Cancer.

Poor association between dihydropyrimidine dehydrogenase ( DPYD ) genotype and fluoropyrimidine‐induced toxicity in an Asian population

T. Kawaguchi, J. Sakamoto, A. Ohtsu, 2022, Cancer medicine.

Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer.

M. Robson, K. Muro, A. Ohtsu, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment outcome and recovery from peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer (JFMC41-1001-C2: JOIN Trial).

J. Sakamoto, K. Goto, Y. Ogata, 2017 .

[Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer].

A. Ohtsu, 2006, Gan to kagaku ryoho. Cancer & chemotherapy.

Computer-Assisted Analysis of Biopsy Specimen Microvessels Predicts the Outcome of Esophageal Cancers Treated with Chemoradiotherapy

S. Yoshida, A. Ochiai, M. Fukayama, 2006, Clinical Cancer Research.

Computer-Assisted Analysis of Biopsy SpecimenMicrovessels Predicts the Outcome of Esophageal Cancers Treatedwith Chemoradiotherapy

A. Ochiai, M. Fukayama, A. Ohtsu, 2006 .

Peroral pancreatoscopy for the diagnosis of pancreatic diseases.

H. Tajiri, A. Ohtsu, M. Ryu, 1998, Pancreas.

EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma.

T. Oyama, N. Kagawa, K. Kaneko, 2010, Frontiers in bioscience.

Phase II study of sequential high-dose methotrexate and fluorouracil combined with doxorubicin as a neoadjuvant chemotherapy for scirrhous gastric cancer

S. Yoshida, A. Ohtsu, T. Kinoshitá, 2001, Gastric Cancer.

Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy.

S. Yoshida, A. Ochiai, A. Ohtsu, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008.

R. Labianca, D. Kerr, J. Berlin, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study.

T. Kohno, T. Yamanaka, Y. Ohe, 2016 .

Quality of life in the trastuzumab for gastric cancer trial.

Y. Bang, E. Van Cutsem, Yoon-Koo Kang, 2014, The oncologist.

Does Daily Alcohol and/or Cigarette Consumption Cause Low-grade Dysplasia, a Precursor of Esophageal Squamous Cell Carcinoma?

K. Kaneko, A. Ohtsu, Y. Murakami, 2010, Journal of clinical gastroenterology.

Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.

A. Ohtsu, M. Tahara, T. Doi, 2009, Japanese journal of clinical oncology.

Phase II study of nivolumab (ONO-4538/BMS-936558) in patients with esophageal cancer: Preliminary report of overall survival.

Y. Doki, K. Muro, A. Ohtsu, 2016 .

K. Kaneko, T. Yano, Y. Oono, 2015, Surgical Endoscopy.

Genetic variations and haplotypes of UGT1A4 in a Japanese population.

Teruhiko Yoshida, N. Saijo, N. Kamatani, 2005, Drug metabolism and pharmacokinetics.

Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial

E. Van Cutsem, J. Tabernero, R. Mayer, 2017, ESMO Open.

Panitumumab in Japanese Patients with Unresectable Colorectal Cancer: A Post-marketing Surveillance Study of 3085 Patients†

A. Gemma, K. Muro, A. Ohtsu, 2014, Japanese journal of clinical oncology.

Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer

I. Hyodo, Y. Arai, A. Ohtsu, 2003, Cancer Chemotherapy and Pharmacology.

Recurrence After Endoscopic Mucosal Resection for Superficial Esophageal Cancer

H. Tajiri, S. Yoshida, A. Ohtsu, 2000, Endoscopy.

A laterally-spreading tumor in a colonic interposition treated by endoscopic submucosal dissection.

K. Kaneko, T. Yano, Y. Oono, 2010, World journal of gastroenterology.

Novel genetic polymorphisms in the NR3C1 (glucocorticoid receptor) gene in a Japanese population.

Teruhiko Yoshida, N. Saijo, A. Ohtsu, 2005, Drug metabolism and pharmacokinetics.

The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced colorectal cancer.

E. Oki, A. Ohtsu, T. Kudo, 2017 .

Neoadjuvant chemotherapy with S-1 for scirrhous gastric cancer: a pilot study

T. Oda, S. Yoshida, A. Ohtsu, 2003, Gastric Cancer.

TS gene tandem repeats in esophageal cancer patients receiving chemoradiotherapy.

T. Oyama, K. Kaneko, A. Ohtsu, 2011, Frontiers in bioscience.

Population pharmacokinetic (PK) analysis of TAS-102 in patients (pts) with metastatic colorectal cancer (mCRC): Results from 3 phase 1 trials and the phase 3 RECOURSE trial.

H. Lenz, R. Mayer, A. Ohtsu, 2015 .

6099 POSTER The Value of Thymidine Kinase 1 (TK1) and Thymidine Phosphorylase (TP) Expression as Predictive Factors With the Treatment Efficacy of TAS-102, a Novel Antitumour Agent, in Patients (pts) With Metastatic Colorectal Cancer (mCRC)

K. Muro, A. Ohtsu, H. Baba, 2011 .

Genetic Variations and Haplotype Structures of the ABCB1 Gene in a Japanese Population: An Expanded Haplotype Block Covering the Distal Promoter Region, and Associated Ethnic Differences

N. Saijo, Y. Ohe, N. Kamatani, 2006, Annals of human genetics.

Long-term results for patients with unresectable gastric cancer who received chemotherapy in the Japan Clinical Oncology Group (JCOG) trials

S. Yoshida, A. Ohtsu, M. Kurihara, 2000, Gastric Cancer.

Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: clinical implications.

Teruhiko Yoshida, S. Yoshida, A. Ochiai, 2006, International journal of oncology.

A pilot study of post-operative radiotherapy with concurrent chemotherapy for high-risk squamous cell carcinoma of the cervical esophagus.

A. Ohtsu, H. Daiko, M. Tahara, 2011, Japanese journal of clinical oncology.

Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors

A. Ohtsu, D. Weinreich, T. Yoshino, 2012, Cancer Chemotherapy and Pharmacology.

Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma

A. Ochiai, A. Ohtsu, H. Daiko, 2017, BMC Cancer.

A case of advanced gastric cancer complicated by severe toxicity induced by a combination of tegafur, uracil and mitomycin C, and associated with abnormal pharmacokinetics.

H. Tajiri, S. Yoshida, K. Kaneko, 1996, Japanese Journal of Clinical Oncology.

The histological basis of detection of adenoma and cancer in the colon by autofluorescence endoscopic imaging.

H. Tajiri, S. Yoshida, A. Ohtsu, 1999, Endoscopy.

Genetic polymorphisms of copper- and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients.

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2009, Drug Metabolism and Pharmacokinetics.

Docetaxel and cisplatin in patients with advanced or recurrent gastric cancer: a multicenter phase I/II study

I. Hyodo, A. Ohtsu, Toshinobu Sato, 2002, Gastric Cancer.

Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan.

T. Yamanaka, K. Tsuchihara, A. Ohtsu, 2012, Japanese journal of clinical oncology.

Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus

K. Kaneko, A. Ohtsu, Takayoshi Ito, 2003, British Journal of Cancer.

Updated results of randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG 9912).

A. Ohtsu, W. Koizumi, A. Sawaki, 2009, Journal of Clinical Oncology.

Effect of RECIST revision on classification of target lesions and overall response in advanced gastric cancer patients

T. Yano, S. Nomura, A. Ohtsu, 2013, Gastric Cancer.

Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing.

Yutaka Suzuki, T. Yamanaka, S. Nomura, 2019, Biomedical reports.

Endoscopic mucosal resection for early adenocarcinoma arising in Barrett's esophagus

S. Yoshida, A. Ochiai, A. Ohtsu, 2001 .

Associations of quality of life (QoL) with adverse events and tumor response in patients with advanced gastric cancer: Exploratory analyses from RAINBOW and REGARD.

C. Fuchs, A. Ohtsu, S. Al-Batran, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy

K. Matsuo, K. Muro, A. Ohtsu, 2013, Journal of Cancer Research and Clinical Oncology.

A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites

H. Matsumoto, A. Ohtsu, T. Yoshino, 2018, BMC Cancer.

RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma: Quality-of-life (QoL) results.

Tae-You Kim, N. Sugimoto, G. Bodoky, 2014 .

An early phase II study of 5-fluorouracil combined with cisplatinum as a second line chemotherapy against metastatic gastric cancer.

A. Ohtsu, T. Fujii, Y. Shimada, 1991, Japanese journal of clinical oncology.

Prognostic factors for PFS in patients with advanced gastric cancer: Using the data from JCOG9912 study.

A. Ohtsu, W. Koizumi, T. Yoshino, 2011 .

Prognostic factors in Japanese patients with advanced gastric cancer using the data from JCOG9912 study.

A. Ohtsu, W. Koizumi, T. Yoshino, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Multicohort phase II KEYNOTE-059 study.

Y. Bang, C. Fuchs, J. Tabernero, 2016 .

Combination of endoscopic mucosal resection and chemoradiotherapy as a nonsurgical treatments for patients with clinical stage I esophageal squamous cell carcinoma

T. Yano, K. Nihei, A. Ohtsu, 2007 .

Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.

S. Nomura, A. Sato, A. Ohtsu, 2018 .

A Phase II study of irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703).

S. Yoshida, I. Hyodo, A. Ohtsu, 2003, Japanese journal of clinical oncology.

Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant

S. Nomura, S. Mimaki, K. Matsushima, 2023, International Journal of Clinical Oncology.

Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients

A. Ohtsu, M. Yoshida, T. Doi, 2012, British Journal of Cancer.

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study

A. Grothey, A. Ohtsu, H. Hochster, 2016, BMC Cancer.

TAS-102 versus placebo (PBO) in patients (pts) ≥65 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the recourse trial.

H. Lenz, J. Tabernero, B. Tran, 2015 .

Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.

Linda Z Sun, Y. Bang, C. Fuchs, 2016 .

Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy

R. Yamashita, S. Mimaki, K. Tsuchihara, 2019, BMC Cancer.

Bevacizumab in Combination With Chemotherapy as First-LineTherapyinAdvancedGastricCancer:ABiomarker EvaluationFromtheAVAGASTRandomizedPhaseIIITrial

Yoon-Koo Kang, Jianming Xu, A. Ohtsu, 2012 .

Gastropexy Reduces Severe Adverse Events After Percutaneous Endoscopic Gastrostomy (PEG)

S. Yoshida, T. Yano, A. Ohtsu, 2007 .

Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines

A. Ohtsu, H. Sasaki, Y. Matsumura, 2016, Oncotarget.

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients.

K. Sugimachi, A. Ohtsu, T. Taguchi, 1998, European journal of cancer.

Diagnostic utility of endoscopic ultrasonography for preoperative rectal cancer staging estimation.

S. Yoshida, K. Kaneko, K. Muro, 1996, Japanese journal of clinical oncology.

Epidermoid metaplasia of the esophagus: endoscopic feature and differential diagnosis.

A. Ochiai, A. Ohtsu, M. Muto, 2011, Hepato-gastroenterology.

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.

M. Shah, E. Van Cutsem, Yoon-Koo Kang, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary squamous cell carcinoma of the stomach: a case report with a review of Japanese and Western literature.

S. Yoshida, K. Muro, A. Ohtsu, 1999, Hepato-gastroenterology.

Trajectory for the Regulatory Approval of a Combination of Pertuzumab Plus Trastuzumab for Pre-treated HER2-positive Metastatic Colorectal Cancer Using Real-world Data.

A. Ohtsu, T. Yoshino, N. Fuse, 2022, Clinical colorectal cancer.

A Phase II Study of Irinotecan in Combination with 120-h Infusion of 5-Fluorouracil in Patients with Metastatic Colorectal Carcinoma : Japan Clinical Oncology Group Study ( JCOG 9703 )

S. Yoshida, I. Hyodo, A. Ohtsu, 2002 .

Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer

K. Matsuo, K. Muro, A. Ohtsu, 2014, Gastric Cancer.

Inter-institutional heterogeneity in outcomes of chemotherapy for metastatic gastric cancer: correlative study in the JCOG9912 phase III trial

A. Ohtsu, Y. Kurokawa, J. Mizusawa, 2016, ESMO Open.

Long-Term Outcomes of Patients with Superficial Esophageal Squamous Cell Carcinoma After Endoscopic Mucosal Resection (EMR)

K. Kaneko, T. Yano, A. Ohtsu, 2008 .

Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer.

A. Ohtsu, Ken Kato, T. Hamaguchi, 2012, Anticancer research.

O2-11-5Phase II Study of Nivolumab (ONO-4538/BMS-936558) for Esophageal Cancer: Clinical activity by PD-L1 expression analysis

Y. Doki, A. Ohtsu, Y. Hamamoto, 2016 .

Twelve novel single nucleotide polymorphisms in the CES2 gene encoding human carboxylesterase 2 (hCE-2).

Teruhiko Yoshida, N. Saijo, A. Ohtsu, 2003, Drug metabolism and pharmacokinetics.

The NCIC CTG and AGITG CO.23 trial: A phase III randomized study of BBI608 plus best supportive care (BSC) versus placebo (PBO) plus BSC in patients (Pts) with pretreated advanced colorectal carcinoma (CRC).

D. Tu, J. Zalcberg, J. Simes, 2014 .

Case Series of Endoscopic Submucosal Dissection (ESD) for Early Remnant Gastric Cancer After Subtotal Gastrectomy

K. Kaneko, T. Yano, H. Ikematsu, 2009 .

The nationwide genomic screening project for gastrointestinal cancer in Japan (GI-SCREEN): Simultaneous identification of KRAS, NRAS, BRAF, and PIK3CA mutation in advanced colorectal cancer (aCRC) (GI-SCREEN 2013-01).

T. Yamanaka, A. Ochiai, A. Ohtsu, 2015 .

Comparison between neoadjuvant chemotherapy followed by surgery (NAC-S) and definitive chemoradiotherapy (CRT) in overall survival for patients with clinical stage II-III esophageal squamous cell carcinoma (ESCC) (JCOG1406-A).

K. Muro, A. Ohtsu, H. Daiko, 2015 .

Gastric Cancer Working Group report.

M. Inoue, A. Ohtsu, Jaw-Town Lin, 2010, Japanese journal of clinical oncology.

Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912)

A. Ohtsu, K. Shirao, T. Doi, 2007 .

Efficacy of Preventive Endoscopic Balloon Dilation for Esophageal Stricture After Endoscopic Resection

T. Yano, A. Ohtsu, T. Chiba, 2011, Journal of clinical gastroenterology.

The Lack of HER-2/neu Oncogene Amplification in Colorectal Malignancies

S. Yoshida, A. Ohtsu, N. Boku, 2003 .

KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Y. Bang, C. Fuchs, J. Tabernero, 2016 .

Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106).

A. Ohtsu, Y. Hamamoto, A. Takashima, 2013, Japanese journal of clinical oncology.

Five-year survivor with liver metastasis from gastric cancer successfully treated with systemic chemotherapy

S. Yoshida, A. Ohtsu, Y. Hamamoto, 2000, Gastric Cancer.

A first-in-human phase I dose-escalation study of MK-1496, first-in-class orally available novel PLK1 inhibitor, in patients with advanced solid tumors.

A. Ohtsu, H. Kotani, H. Murakami, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study.

E. Oki, T. Yamanaka, Y. Ohashi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response of the primary lesion in gastric cancer to chemotherapeutic trials

S. Yoshida, A. Ohtsu, M. Kurihara, 1998, International Journal of Clinical Oncology.

Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Y. Bang, C. Fuchs, J. Tabernero, 2015 .

Improvement of patient care using cancer genomic profiling: SCRUM-/CIRCULATE-Japan experience

K. Goto, A. Ohtsu, T. Yoshino, 2023, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics).

T. Yamanaka, S. Nomura, H. Esumi, 2015 .

Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution.

A. Ohtsu, T. Yoshino, T. Doi, 2016, Clinical colorectal cancer.

Exploratory analysis of the effect of FTD/TPI in patients treated in RECOURSE by prognostic factors.

J. Tabernero, R. Mayer, A. Ohtsu, 2019, Journal of Clinical Oncology.